Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine

Dorosti, Hesam; Eslami, Mahboobeh; Negahdaripour, Manica; Ghoshoon, Mohammad Bagher; Gholami, Ahmad; Heidari, Reza; Dehshahri, Ali; Erfani, Nasrollah; Nezafat, Navid; Ghasemi, Younes

doi:10.1080/07391102.2018.1519460

Cited by 97 publications

(74 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent advancements in computational biology have opened up new doors for designing effective vaccines in silico. [19][20][21]. In this study, the in silico approach has been applied for attaining a multi-epitope vaccine against SARS-CoV-2 that comprises epitopes of spike glycoprotein epitopes which induces the activation of cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs) and interferon-γ (IFN-γ) ( Fig.…”

Section: Introductionmentioning

confidence: 99%

A Candidate multi-epitope vaccine against SARS-CoV-2

Narsaria

Basak

et al. 2020

Preprint

View full text Add to dashboard Cite

In the past two decades, 7 coronaviruses have infected the human population, with two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively. Currently, the entire world is facing a pandemic of another coronavirus, SARS-CoV-2, with a high fatality rate. The spike glycoprotein of SARS-CoV-2 mediates entry of virus into the host cell and is one of the most important antigenic determinants, making it a potential candidate for a vaccine. In this study, we have computationally designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2. The overall quality of the candidate vaccine was validated in silico and Molecular Dynamics Simulation confirmed the stabilityof the designed vaccine. Docking studies revealed stable interactions of the vaccine with Toll Like Receptors and MHC Receptors. Codon optimization was used to optimize high expression of the vaccine in E.coli K-12 strain. In silico cloning suggested efficient expression in pET-28a (+) vector. The efficiency of the candidate vaccine to trigger an effective immune response was assessed by an in silico immune simulation. The computational analyses suggest that the designed multi-epitope vaccine is structurally stable which can induce specific immune responses and thus, can be a potential vaccine candidate against SARS-CoV-2.Authors Tamalika Kar, Utkarsh Narsaria, Srijita Basak, and Debashrito Deb contributed equally to this work.

show abstract

Section: Introductionmentioning

confidence: 99%

A Candidate multi-epitope vaccine against SARS-CoV-2

Narsaria

Basak

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…These epitope-based vaccines have added advantages of being safe, stable, highly specific, cost-curtailing, easy to produce in bulk, and provides option to manipulate the epitopes for designing of a better vaccine candidate [61]. This method of vaccine development has proved to be promising enough for different microbial diseases including both bacterial and viral [25,[62][63][64][65][66][67].…”

Section: Discussionmentioning

confidence: 99%

Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes

Jain

Shankar

Majee

et al. 2020

Preprint

View full text Add to dashboard Cite

Novel SARS coronavirus (SARS-CoV-2) has caused a pandemic condition world-wide and has been declared as public health emergency of International concern by WHO in a very short span of time. The community transmission of this highly infectious virus has severely affected various parts of China, Italy, Spain and USA among others. The prophylactic solution against SARS-CoV-2 infection is challenging due to the high mutation rate of its RNA genome. Herein, we exploited a next generation vaccinology approach to construct a multi-epitope vaccine candidate against SARS-CoV-2 with high antigenicity, safety and efficacy to combat this deadly infectious agent. The whole proteome was scrutinized for the screening of highly conserved, antigenic, non-allergen and non-toxic epitopes having high population coverage that can elicit both humoral and cellular mediated immune response against COVID-19 infection. These epitopes along with four different adjuvants were utilized to construct a multi-epitope vaccine candidate that can generate strong immunological memory response having high efficacy in humans. Various physiochemical analyses revealed the formation of a stable vaccine product having a high propensity to form a protective solution against the detrimental SARS-CoV-2 strain with high efficacy. The vaccine candidate interacted with immunological receptor TLR3 with high affinity depicting the generation of innate immunity. Further, the codon optimization and in silico expression show the plausibility of the high expression and easy purification of the vaccine product. Thus, this present study provides an initial platform of the rapid generation of an efficacious protective vaccine for combating COVID-19.

show abstract

“…There are several conserved proteins [51] among different S. pneumoniae serotypes, most of them are surface proteins such as PspA, CbpA, and PhtD [52]. In this regard, in our previous immunoinformatic study, the immunodominant epitopes were selected from four antigens, PspA, CbpA, PhtD, and PiuA [53]. Recently, epitope-based vaccines have been introduced as a safer alternative to previous types of vaccines.…”

Section: Discussionmentioning

confidence: 99%

Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy

Dorosti

Eslami

Nezafat

et al. 2019

Molecular and Cellular Probes

Self Cite

View full text Add to dashboard Cite

A B S T R A C TStreptococcus pneumoniae is the main cause of diseases such as meningitis, pneumoniae and sepsis, especially in children and old people. Due to costly antibiotic treatment, and increasing resistance of pneumococcus, developing high-efficient protective vaccine against this pathogen is an urgent need. Although the pneumoniae polysaccharide vaccine (PPV) and pneumonia conjugate vaccines (PCV) are the efficient pneumococcal vaccine in children and adult groups, but the serotype replacement of S. pneumoniae strains causes the reduction in efficacy of such vaccines. For overcoming the aforesaid drawbacks epitope-based vaccines are introduced as the relevant alternative. In our previous research, the epitope vaccine was designed based on immunodominant epitopes from PspA, CbpA antigens as cellular stimulants and PhtD, PiuA as humoral stimulants. Because the low immunogenicity is the main disadvantage of epitope vaccine, in the current study, we applied coiled-coil selfassembled structures for developing our vaccine. Recently, self-assembled peptide nanoparticles (SAPNs) have gained much attention in the field of vaccine development due to their multivalency, self-adjuvanticity, biocompatibility, and size similarity to pathogen. In this regard, the final designed vaccine is comprised of cytotoxic T lymphocytes (CTL) epitopes from PspA and CbpA, helper T lymphocytes (HTL) epitopes from PhtD and PiuA, the pentamer and trimmer oligomeric domains form 5-stranded and 3-stranded coiled-coils as self-assembled scaffold, Diphtheria toxoids (DTD) as a universal T-helper, which fused to each other with appropriate linkers. The four different arrangements based on the order of above-mentioned compartments were constructed, and each of them were modeled, and validated to find the 3D structure. The structural, physicochemical, and immunoinformatics analyses of final vaccine construct represented that our vaccine could stimulate potent immune response against S. pneumoniae; however, the potency of that should be approved via various in vivo and in vitro immunological tests.

show abstract

Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine

Cited by 97 publications

References 85 publications

A Candidate multi-epitope vaccine against SARS-CoV-2

A Candidate multi-epitope vaccine against SARS-CoV-2

Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes

Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy

Contact Info

Product

Resources

About